ClinPharm Consulting is offering new services to enable biopharmaceutical companies to reduce drug development risks and maximize return on R&D investment.
The services are derived from insights into preventable issues revealed by the firm’s clinical pharmacology and PK-PD work across numerous client projects.
“Our new services arise from important concepts that our clients are seeking, including sound strategic and scientific advice and rapid delivery of services at an affordable cost,” said ClinPharm Consulting’s Chief Scientific Officer, Bill Wargin, PhD, adding, “We’re developing proactive solutions to help avoid development delays for companies and maximize their return on R&D investment.”
The new services offered by ClinPharm Consulting include the following:
In addition to these new services, ClinPharm Consulting is seeing growing interest in customized clinical pharmacology plans to address important issues and prevent delays in clinical studies, providing a road map to clients’ programs and identifying key areas to avoid risk.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.